Skip to main content

Dental Implants

0
Pipeline Programs
5
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Geistlich Pharma
Geistlich PharmaSwitzerland - Root
2 programs
Connective Tissue GraftN/A1 trial
Immediate implant and socket preservationN/A1 trial
Active Trials
NCT07324187Completed36Est. Apr 2025
NCT01107600Withdrawn0Est. Jun 2011
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Combining a strip free gingival graftN/A1 trial
Active Trials
NCT07346391RecruitingEst. Jul 2026
Innovation Pharmaceuticals
1 program
Connective Tissue GraftN/A
MIS Implants Technologies
1 program
Control GroupN/A1 trial
Active Trials
NCT07498556Not Yet Recruiting50Est. Dec 2027
Orchard Therapeutics
1 program
OSSIX VolumaxN/A1 trial
Active Trials
NCT06187805Unknown15Est. Feb 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
MIS Implants TechnologiesControl Group
City TherapeuticsCombining a strip free gingival graft
Orchard TherapeuticsOSSIX Volumax
Geistlich PharmaConnective Tissue Graft
Geistlich PharmaImmediate implant and socket preservation

Clinical Trials (5)

Total enrollment: 101 patients across 5 trials

NCT07498556MIS Implants TechnologiesControl Group

Immediate Restoration of a New Implant With High Primary Stability

Start: Mar 2026Est. completion: Dec 202750 patients
N/ANot Yet Recruiting
NCT07346391City TherapeuticsCombining a strip free gingival graft

Augmentation of Peri-implant Keratinized Mucosa Using a Combination of Free Gingival Graft Strip With Platelet-Rich Fibrin

Start: Dec 2025Est. completion: Jul 2026
N/ARecruiting
NCT06187805Orchard TherapeuticsOSSIX Volumax

Retrospective Case Series - OSSIX Volumax Collagen Xenograft Scaffolding

Start: Nov 2023Est. completion: Feb 202415 patients
N/AUnknown
NCT07324187Geistlich PharmaConnective Tissue Graft

CTG vs VCMX for Peri-implant Soft Tissue Thickness

Start: Jan 2022Est. completion: Apr 202536 patients
N/ACompleted
NCT01107600Geistlich PharmaImmediate implant and socket preservation

Study on Immediate Loading of Immediately Placed Single Implants.

Start: Jun 2010Est. completion: Jun 20110
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 101 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.